{"entity":{"id":"nct07398664","kind":"trial","name":"H101 Plus TACE for r/m HNSCC","aka":[],"tldr":"A phase 2 trial of H101 oncolytic adenovirus in Head and neck squamous cell carcinoma, run by West China Hospital, now recruiting.","summary":"H101 Plus TACE for r/m HNSCC is a phase 2 interventional study registered as NCT07398664 by West China Hospital, with 20 participants planned, started 2026-03-02 and due to reach its primary completion in 2028-06-15. Interventions recorded: H101, TACE. Conditions recorded: Head and Neck Squamous Cell Carcinoma, Oncolytic Virus, TACE.\n\nLinked to the drug H101 oncolytic adenovirus because the registry names it among its interventions and Head and neck squamous cell carcinoma among its conditions. Registry record only: no result has been read by an editor.","status":"recruiting","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT07398664","url":"https://clinicaltrials.gov/study/NCT07398664"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":["h101-oncolytic-adenovirus"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07398664","phase":"2","setting":"Recombinant Human Adenovirus 5 (H101) Combined With Transcatheter Arterial Chemoembolization (TACE) for the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Single-Center, Prospective Study","sponsor":"West China Hospital","enrolled":20,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07398664/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}],"drug":[{"id":"h101-oncolytic-adenovirus","kind":"drug","name":"H101 oncolytic adenovirus","route":"/drugs/h101-oncolytic-adenovirus/"}]}}